Spots Global Cancer Trial Database for A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
Official Title: A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
Study ID: NCT00915083
Conditions
Interventions
Study Description
Brief Summary: The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors. The study will assess the pharmacokinetics of the amrubicin and if it has an effect on the heart.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California San Diego, La Jolla, California, United States
Sarcoma Oncology Center, Santa Monica, California, United States
Indiana University Cancer Pavilion, Indianapolis, Indiana, United States
James Graham Brown Cancer Center, Louisville, Kentucky, United States
Sinai Hospital of Baltimore- Alvin and Lois Lapidus Cancer Institute, Baltimore, Maryland, United States
Montefiore Medical Center, Bronx, New York, United States
UT Health Science Center at San Antonio- Cancer Therapy and Research Center, San Antonio, Texas, United States
Hunstman Cancer Institute, Salt Lake City, Utah, United States
Contact Details
Name: Markus Renschler, MD
Affiliation: Celgene Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
